Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 6/20 | 0.53 |
| ▸ | CYP24A1 | Q07973 | 11/20 | 0.50 |
| ▸ | CYP27B1 | O15528 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19054884 | 0.87 | MAPT (0.56) | CYP17A1CYP24A1CYP27B1KDM4E | |
| SCHEMBL20390011 | 0.86 | CYP19A1 (0.54) | CYP17A1CYP24A1CYP19A1KDM4E | |
| SCHEMBL20390012 | 0.83 | CYP17A1 (0.49) | CYP17A1CYP24A1KDM4E | |
| SCHEMBL410598 | 0.82 | CYP17A1 (0.56) | CYP17A1CYP24A1CYP27B1CYP19A1KDM4E | |
| SCHEMBL6983161 | 0.82 | CYP24A1 (0.56) | CYP17A1CYP24A1CYP27B1CYP19A1KDM4E | |
| SCHEMBL27550789 | 0.80 | CYP19A1 (0.50) | CYP17A1CYP24A1CYP19A1KDM4E | |
| SCHEMBL5297627 | 0.77 | CYP17A1 (0.82) | CYP17A1CYP19A1 | |
| SCHEMBL1913708 | 0.77 | ALDH1A1 (0.44) | CYP24A1KDM4E | |
| SCHEMBL19054886 | 0.77 | CYP19A1 (0.55) | CYP17A1CYP19A1 | |
| SCHEMBL19054890 | 0.77 | CYP17A1 (0.56) | CYP17A1CYP24A1CYP27B1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | LES LABORATORIES SERVIER (FR) | 2003-10-23 | — | — | US | disclosed |
| CN-1445226-A | New cornpound derivated from quinazoline, itd preparation method and medicinal composite containig them | ADIR (FR) | 2003-10-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | NQO2, XDH, DRD1 | CYP17A1 3127/4885CYP24A1 2355/4885CYP27B1 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.